FDA OKs Qiagen's companion Dx for Boehringer lung cancer drug

07/15/2013 | GenomeWeb Daily News (free registration)

The FDA granted Qiagen approval to market its Therascreen EGFR test as a companion diagnostic test for Gilotrif, or afatinib, a drug for metastatic nonsmall-cell lung cancer developed by Boehringer Ingelheim. The assay is designed to determine which patients will benefit from Gilotrif.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC